A Message from VGXI Regarding the Coronavirus (COVID-19) Outbreak and VGXI Actions LAST UPDATED May 14, 2021 To our Valued Clients and Business Partners, VGXI recognizes your concerns regarding the potential impact of the coronavirus outbreak on our products and services. VGXI is actively monitoring the situation and will continue to provide updates as new… Read More »
VGXI Official Statement Regarding COVID-19
VGXI to Exhibit at the 2019 BIO International Convention
With over 16,000 attendees, BIO is one of the largest biotech partnering, education, and networking events in the world. Be sure to stop by VGXI’s Booth #3349 or schedule a meeting with one of our representatives during the conference to learn how VGXI’s plasmid manufacturing services can support your gene or cell therapy program! Contact Us directly or use BIO’s One-On-One… Read More »
VGXI Announces Continued Progress for RNA Manufacturing Partnership
Texas based CMO VGXI Announces Completion of Initial Tech Transfer Milestones as part of its Partnership Agreement for Production of RNA Therapeutics with HMRI. March 15, 2019, The Woodlands, TX – Under a license agreement with the Houston Methodist Research Institute (HMRI) for development of clinical grade RNA manufacturing services, VGXI announced it has completed… Read More »
Visit VGXI at Phacilitate Leaders World 2019
Combined with the World Stem Cell Summit, Phacilitate Leaders World is the worlds largest advanced therapies partnering event. Stop by VGXI’s Booth # 713 to meet with representatives from our company and learn more about our plasmid manufacturing products and services! We welcome meeting requests through the Phacilitate partnering website, or contact Us today to schedule a meeting time…. Read More »
New White Paper Released – Stability of Plasmid DNA Products
Stability of Plasmid DNA Products: A Review of the Data For any pharmaceutical product, an important consideration is the handling and environmental conditions that the material may experience from the time it is manufactured until final dosing of a patient. Plasmid DNA is generally recognized to have exceptional stability compared to other biologics such as… Read More »
New White Paper Released – Calculating your DNA plasmid needs.
Calculating the amount of plasmid DNA needed for a clinical trial may seem straightforward – simply multiply the dose by the number of doses to be administered. However, there are many factors to consider, and the required production scale may be several times the amount needed for clinical dosing. This white paper walks through one case study to illustrate how much plasmid… Read More »
Second Generation DNA Vaccines and Delivery Methods
Second Generation DNA Vaccines DNA vaccines have come a long way resulting in a second generation of vast improvements bringing a surge of interest to the community. In both small and large animal models, second-generation DNA vaccines show that they assist cellular and humoral immune responses. Additionally, research suggests that newer DNA vaccines can more… Read More »
Vaccines Have Been Known to Prevent Disease, What if they could Treat Disease?
Traditional vaccines are designed to prevent disease; researchers are working on something new: therapeutic vaccines, vaccinations that treat a disease after you have it. Currently, vaccine research is underway to use therapeutic vaccines to medically treat diseases such as: HIV, Herpes, Alzheimer’s disease and cancer Standard preventative vaccines work by helping your immune system develop… Read More »
[BLOG] Dengue Fever 101
Since it became a global issue during World War II, researchers and scientists have been struggling to develop a vaccine for Dengue fever. To date, there has been no success in eradicating this disease. Before we get to the specifics of the challenges this disease presents, let’s cover the symptoms related to this tropical disease…. Read More »
DNA Vaccine for Malaria Demonstrates Ability to Kill Infected Cells
A new potential vaccine for malaria is gaining media attention after successful pre-clinical trials in small animals and non-human primates. Until now, the most effective malaria vaccine in human clinical trials has been GSK’s RTS,S vaccine. Their vaccine demonstrated a 50% efficacy in children between the ages of 5 and 17 months and only a 30%… Read More »
Brazilian DNA Vaccine for AIDS to be Tested in Rhesus Monkeys
In development since 2001, the HIVBr18 DNA vaccine developed at the Medical School at the University of Sao Paulo (USP) in Brazil may prevent transmission of human immunodeficiency virus (HIV) and development of acquired immune deficiency syndrome (AIDS). The DNA Vaccine encodes 18 conserved multiple HLA-DR-binding HIV-1 CD4 epitopes capable of eliciting broad CD4(+) T… Read More »
Combination Cell & Gene Therapy for Brain Metastases of Breast Cancer
New research out of the UCLA Jonsson Comprehensive Cancer Center (JCCC) led by Carol Kruse, professor of neurosurgery, combined two therapies currently undergoing individual clinical trials to determine if the two used in tandem could demonstrate a greater efficacy and reduction of tumor size than either therapy alone. Dr. Kruse’s combination therapy includes both a… Read More »